20.08.2023, 713 Zeichen

Valneva: Valneva, an Austrian/French specialty vaccine company, announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA) action date for the Biologics License Application (BLA) for VLA1553, Valneva’s chikungunya virus vaccine candidate, from the previously communicated end of August to the end of November. The FDA extended the PDUFA date to allow sufficient time to align and agree on the phase 4 program necessary under the accelerated approval pathway. No additional clinical data have been requested for the approval process.
Valneva: weekly performance: -11.29%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/08/2023)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #856: ATX TR 10.000, wie wärs mir einer PK? Wir haben O-Töne zum Rekord und Palfinger erwähnt Rheinmetall

Bildnachweis

Aktien auf dem Radar:Strabag, Frequentis, Porr, EuroTeleSites AG, Pierer Mobility, Agrana, OMV, Semperit, CA Immo, Immofinanz, Verbund, Andritz, AT&S, Bawag, BTV AG, Erste Group, Gurktaler AG VZ, Lenzing, Palfinger, Österreichische Post, voestalpine, Wienerberger, Wolford, Zumtobel, BKS Bank Stamm, Oberbank AG Stamm, Austriacard Holdings AG, Amag, EVN, Flughafen Wien, Telekom Austria.

---